Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...

Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 ...

A naturally occurring molecule that works as effectively as other semaglutide-based drugs — without the common side effects — ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

The researchers focused on the enzyme prohormone convertase 1/3, which plays a role in obesity and produces peptides like GLP-1, the target of semaglutide. Using an AI algorithm called Peptide ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before ...

Let’s dive in. Semaglutide is in a class called glucagon-like peptide-1 (GLP-1) receptor agonists. It works by mimicking GLP-1, a hormone the intestines naturally make. GLP-1 plays a key role in ...